Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Self-Administered TEV-48125 in Japanese Migraine Patients
NCT04355117Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of fremanezumab in migraine, sponsored by Otsuka Pharmaceutical Co., Ltd.. Started Jun 2020; status: completed.
02
Drugs
fremanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04355117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04355117.